Limerick BioPharma Receives $3,050,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8f94a9ba-9a33-4435-96b3-6954e679ff05&Preview=1 - Date
7/26/2011 - Company Name
Limerick BioPharma - Mailing Address
601 Gateway Blvd. South San Francisco, CA 94080 - Company Description
Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients’ lives. Our compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug’s desired effects. In the monotherapy setting, we are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia. - Website
http://www.limerickbio.com - Transaction Type
Debt, Venture Equity - Transaction Amount
$3,050,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. Amount may include options, warrants or other rights to acquire other securities. SEC regulatory filing-amended. - M&A Terms
- Venture Investor
Undisclosed
